Crinetics Pharmaceuticals (CRNX) Share-based Compensation (2017 - 2026)

Crinetics Pharmaceuticals' Share-based Compensation history runs 10 years deep, the most recent figure standing at $29.7 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 44.94% year-over-year to $29.7 million; the TTM figure through Mar 2026 stood at $100.2 million (up 31.17% YoY), while the FY2025 annual figure was $91.0 million, up 31.18% from the prior year.
• Share-based Compensation was $29.7 million for Q1 2026 at Crinetics Pharmaceuticals, up from $21.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $29.7 million in Q1 2026 to a low of $5.8 million in Q1 2022.
• Historically, Share-based Compensation has averaged $15.3 million across 5 years, with a median of $13.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 86.14% in 2024, then climbed 15.26% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $7.9 million in 2022, then surged by 46.16% to $11.6 million in 2023, then jumped by 62.22% to $18.8 million in 2024, then advanced by 15.26% to $21.7 million in 2025, then soared by 36.65% to $29.7 million in 2026.
• The last three Share-based Compensation figures came in at $29.7 million (Q1 2026), $21.7 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.